Bio-adhesive dissolving compounds and device

ABSTRACT

A medical device may comprise a body including a mixture of polyvinylpyrrolidone (“PVP”) and mitomycin. The medical device may be in any size or shape such that the medical device may be inserted into living tissue, including, but not limited to, a lacrimal punctal plug and a stent. The mixture of PVP and mitomycin may be coated on a portion of the medical device, contained within a cavity on the medical device, disposed on the surface of the medical device or configured as part of the medical device such that the mixture of PVP and mitomycin can be delivered to tissue.

CROSS-REFERENCE TO RELATED APPLICATION

n/a

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

n/a

FIELD OF INVENTION

The present application is related to a method and device with drugdelivery capabilities.

BACKGROUND OF THE INVENTION

Mitomycins are a family of aziridine-containing natural productsisolated from Streptomyces caespitosus or Streptomyces lavendulae.Mitomycin may be used to treat a variety of different types if disordersand conditions associated with the growth and spread of cells. The term“mitomycin” may include mitomycin A, mitomycin B, and mitomycin C.

Mitomycin can inhibit the growth of cells within the body. Varioustreatments have used mitomycin including in chemotherapy, for modulatingwound healing after ophthalmological surgeries, and in the management ofvarious corneal disorders. Patients have successfully treated andmanaged conditions and symptoms when using mitomycin including forpancreatic, stomach, breast, bladder, esophagus, lung, anal, and livercancers, gastrointestinal strictures, endoscopic dacryocystorhinostomy,scarring issues, as well as to modify wound healing from glaucomasurgery and in corneal excimer laser surgery.

Patients and medical providers face a variety of different challengeswhen treatments incorporate mitomycin. For example, the costs associatedwith drug therapies that include mitomycin can be extremely expensive.Purchasing even a small quantity of mitomycin can cost a significantamount of money and can be difficult for a patient and/or medicalprovider to purchase. Also, the costs associated with medications areconstantly increasing, which can lead some patients to be faced with thechoice of purchasing basic necessities, paying for medications, and/ormedical treatments which can significantly impact their activities ofdaily living. Many insurance companies will not cover the full cost ofmedical procedures and/or the drugs used during medical procedures andtherefore patient's sometimes must to make difficult decisions.

Mitomycin is soluble in water and can undergo rapid degradation incertain solutions. With this rapid degradation, it can be difficult todeliver the drug effectively and efficiently to a patient, because ofdose variations due to active pharmaceutical ingredient (“API”)degradation. To avoid under dosing, treatments using mitomycin must beprepared shortly before use and then used in the treatment quickly toavoid the breakdown of the mitomycin. For example, if mitomycin is usedas part of a chemotherapeutic regime, the mitomycin must be combinedwith the other drugs very shortly before use and/or administration. Ifthe mitomycin is not used quickly, it can breakdown and can reduce theeffectiveness of the treatment.

Also, mitomycin can be toxic to the medical provider and avoiding anycontact with the drug is the safest option for a medical provider.Mitomycin may be harmful if it comes into contact with the skin, eyes,or is swallowed and is a suspected carcinogenic agent. Strict safetyprecautions are to be followed by medical providers when handling thisdrug. For example, protective gear is often worn by a medical providerwhen s/he comes into contact with mitomycin including protective gloves,protective clothing, eye protection, and face protection. Additionally,medical providers are advised to wash hands and other body partsthoroughly after handling or otherwise coming into contact withmitomycin, even if protective gear is worn.

When mitomycin is used during surgery, it is often applied to tissueusing a sponge which does not provide targeted and direct treatment toparticular tissue using the mitomycin. When applied using a sponge, themitomycin can ooze out onto tissue and unnecessarily expose tissue tomitomycin that was not intended to come into contact with the drug.Medical providers often copiously irrigate the tissue that wasunnecessarily exposed to the mitomycin to try and prevent harm to thetissue that was not intended to come into contact with the mitomycin.

SUMMARY

The present invention advantageously provides a method and system for amedical device for the delivery of drugs to a patient. A medical devicemay comprise a body including a mixture of polyvinylpyrrolidone (“PVP”)and mitomycin.

In one aspect of the embodiment, the medical device may have the mixtureof PVP and mitomycin coated on at least a portion of the body.

In one aspect of the embodiment, the medical device may further comprisean exterior coating where the mixture of PVP and mitomycin are coatedwith the exterior coating.

In one aspect of the embodiment, the exterior coating may be lubricious.

In one aspect of the embodiment, the body may include an elongateportion.

In one aspect of the embodiment, the elongate portion may have a firstportion and a second portion. The first portion of the elongate portionmay have a rounded first end.

In one aspect of the embodiment, the second portion has a second end,the second end being expandable from a first diameter to a seconddiameter.

In one aspect of the embodiment, the body may define a cavity, themixture of the PVP and the mitomycin may be disposed within the cavity.

In one aspect of the embodiment, the medical device may further includea bioabsorbable membrane enclosing at least a portion of the cavity.

In one aspect of the embodiment, the body may have a surface, thesurface including at least one aperture.

In one aspect of the embodiment, the medical device may be a lacrimalpunctal plug.

In one aspect of the embodiment, the body may be a stent.

In another embodiment, the medical device may comprise an elongate bodysized to be received within a lacrimal punctum; a cavity within at leasta portion of the body, the cavity having at least one opening and atleast a portion of the cavity including a mixture of PVP and mitomycin;and a bioabsorbable membrane enclosing the at least one opening.

In one aspect of the embodiment, at least a portion of the bioabsorbablemembrane may be lubricious.

In one aspect of the embodiment, the elongate body may have a firstportion and a second portion opposite the first portion. The elongatebody may be cylindrical and taper in diameter from the first portion tothe second portion.

In one aspect of the embodiment, the first portion may have a first end,the first end being expandable from a first diameter to a seconddiameter.

In one aspect of the embodiment, the elongate body may have a diameterand the first end has a first diameter that may be at least one of thegroup consisting of greater than, equal to, and less than the diameterof the elongate body. The second portion may have a second end oppositethe first end with a second end diameter that is greater than thediameter of the elongate body.

In one aspect of the embodiment, at least one of the group consisting ofthe first end and the second end is collapsible.

In one aspect of the embodiment, the medical device may further includea bioabsorbable coating. The mixture of the PVP and mitomycin may beprovided with the bioabsorbable coating.

In another embodiment, a method for inserting a medical device intoliving tissue where the method includes: inserting a body into a livingtissue, the body including a mixture of polyvinylpyrrolidone (“PVP”) andmitomycin; advancing the body in the living tissue; allowing the mixtureof PVP and mitomycin to disperse in the living tissue; and removing thebody from the living tissue.

The details of one or more aspects of the disclosure are set forth inthe accompanying drawings and the description below. Other features,objects, and advantages of the techniques described in this disclosurewill be apparent from the description and drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

A more complete understanding of the present invention, and theattendant advantages and features thereof, will be more readilyunderstood by reference to the following detailed description whenconsidered in conjunction with the accompanying drawings wherein:

FIG. 1 illustrates an embodiment of a medical device in accordance withthe present invention;

FIG. 2 illustrates a stability studies results for PVP films containingmitomycin;

FIGS. 3A and 3B illustrate another embodiment of the medical device inaccordance with the present invention;

FIG. 4 illustrates another embodiment of the medical device inaccordance with the present invention;

FIG. 5 illustrates another embodiment of the medical device inaccordance with the present invention;

FIG. 6 illustrates another embodiment of the medical device inaccordance with the present invention;

FIG. 7 illustrates another embodiment of the medical device inaccordance with the present invention;

FIG. 8 illustrates another embodiment of the medical device inaccordance with the present invention; and

FIG. 9 is an exemplary method for inserting the medical device intoliving tissue.

DETAILED DESCRIPTION

The system and methods disclosed herein are for a device and system forthe delivery of compounds using water-soluble bio-adhesive dissolvingpolymers. Specifically, described herein are medical devices that canhave various bio-adhesive dissolving compounds. While the figures showexemplary medical devices that can be used with the bio-adhesivedissolving compounds, these are non-limiting examples of water solublebio-adhesive dissolving compounds that can be used with a variety ofother and different medical devices.

Before describing in detail exemplary embodiments that are in accordancewith the disclosure, it is noted that components have been represented,where appropriate, by conventional symbols in drawings, showing onlythose specific details that are pertinent to understanding theembodiments of the disclosure so as not to obscure the disclosure withdetails that will be readily apparent to those of ordinary skill in theart having the benefit of the description herein.

As used herein, relational terms, such as “first,” “second,” “top” and“bottom,” and the like, may be used solely to distinguish one entity orelement from another entity or element without necessarily requiring orimplying any physical or logical relationship or order between suchentities or elements. The terminology used herein is for the purpose ofdescribing particular embodiments only and is not intended to belimiting of the concepts described herein. As used herein, the singularforms “a”, “an”, and “the” are intended to include the plural forms aswell, unless the context clearly indicates otherwise. It will be furtherunderstood that the terms “comprises,” “comprising,” “includes”, and/or“including” when used herein, specify the presence of stated features,integers, steps, operations, elements, and/or components, but do notpreclude the presence or addition of one or more other features,integers, steps, operations, elements, components, and/or groupsthereof.

Unless otherwise defined, all terms (including technical) used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure belongs. It will be further understoodthat terms used herein should be interpreted as having a meaning that isconsistent with their meaning in the context of this specification andthe relevant art and will not be interpreted in an idealized or overlyformal sense unless expressly so defined herein.

It should be understood that various aspects disclosed herein may becombined in different combinations than the combinations specificallypresented in the description and accompanying drawings. It should alsobe understood that, depending on the example, certain processes ormethods described herein may be performed in a different sequence, maybe added, merged, or left out altogether.

It should be understood that various aspects disclosed herein may becombined in different combinations than the combinations specificallypresented in the description and accompanying drawings. It should alsobe understood that, depending on the example, certain acts or events ofany of the processes or methods described herein may be performed in adifferent sequence, may be added, merged, or left out altogether (e.g.,all described acts or events may not be necessary to carry out thetechniques). In addition, while certain aspects of this disclosure aredescribed as being performed by a single module or unit for purposes ofclarity, it should be understood that the techniques of this disclosuremay be performed by a combination of units or modules associated with,for example, a medical device.

Referring now to the drawings in which like reference designators referto like elements, there is shown in FIG. 1, an exemplary medical systemconstructed in accordance with the principles of the present applicationand designated generally as “10.” The medical device 10 may have a body12 and the body 12 may be any size and may have any myriad of shapesdepending on how and where the body 12 and medical device 10 is to beused in a patient. For example, as shown in FIG. 1, the body 12 may bean elongate body configured to be inserted into an orifice or other bodytissue. The body 12 may include a mixture of polyvinylpyrrolidone(“PVP”) 14 and mitomycin 16. The mixture of PVP 14 and mitomycin 16 maybe coated on at least a portion of the body 12. Alternatively, themixture of PVP 14 and mitomycin 16 may be coated on the entire body 12.How and where the mixture of PVP 14 and mitomycin 16 is coated maydepend upon what the mitomycin 16 is being used to treat and where inthe body the mitomycin 16 is being used. For example, if the mixture ofPVP 14 and mitomycin 16 is being used in an eye, this may require adifferent coating of the mixture than if it is being used in a medicaldevice 10 that is to be inserted into the bladder.

Continuing to refer to FIG. 1, when PVP 14 is mixed with mitomycin 16this mixture can create a bio-adhesive film 18 that can hold themitomycin 16 in place, stabilize the mitomycin 16, and release themitomycin 16 when water, or aqueous body fluids are added to the mixtureof PVP 14 and mitomycin 16. For example, if the mixture of PVP 14 andmitomycin 16 are added to a patient's tissue that includes water oraqueous body fluids, the mitomycin 16 may be released from the mixture.An exterior coating 20 may also coat the mixture of PVP 14 and mitomycin16 on the medical device 10. This exterior coating 20 may be lubricousor alternatively it may not be slippery.

Continuing to refer to FIG. 1, when referring to mitomycin 16 in theapplication, this may refer to mitomycin A, mitomycin B, and/ormitomycin C. Mitomycin 16 is soluble in water at 0.5 mg/mL at a pH ofbetween 6.0 and 7.5. Also, mitomycin 16 may undergo rapid degradation inacidic solutions with a pH of less than 6 and when exposed to light. Ingeneral, mitomycin 16 is unstable and may only last up to one week whenrefrigerated between 2° C. and 8° C. without being exposed to light.When mitomycin 16 is formulated with PVP, the mixture of mitomycin 16and PVP 14 may be stable for long periods of time. Mitomycin 16 alone isa very unstable compound and decomposes very quickly. This can make itdifficult to use the mitomycin 16 in medical treatments as it breaksdown quickly. However, when mitomycin 16 is mixed and/or blended withPVP 14 this mixture may be made into a film. As seen in FIG. 2, theactive pharmaceutical ingredient (“API”) API/polymer matrix is stableunder ambient temperatures as well as with the presence of humidity forweeks at a time. Bio-adhesive structures composed of PVP 14 andmitomycin 16 stabilizes the mitomycin 16 for long-periods of time andslows down the decomposition of the mitomycin 16. As a non-limitingexample, the API/polymer matrix is stable in a plastic or aluminumenvelope, protected from light under ambient temperature as well as inthe present of ambient humidity (<30% relative humidity) for weeks at atime. This slowing down of the decomposition of the mitomycin 16 may befor weeks, months, and/or years.

Now referring to FIG. 2, this table is an exemplary stability studyshowing the stability of the mixture of mitomycin 16 and PVP 14. Thestudy was done over a one-hundred and eighty-five (185) day period anddemonstrates the stability of this mixture over this period of time. Inthis exemplary stability study, a mitomycin 16 solution may be preparedusing 30 mg of mitomycin and 29.970 grams of absolute ethanol. 1.0mg/gram of the mixture of the 30 mg of mitomycin and 29.970 grams ofabsolute ethanol may be added to 1.360 grams of Kollidon-90F (PVP) and0.090 grams of Kollidon®-VA64 (PVP copolymer). This mixture whichincludes PVP 14 and mitomycin 16 may be used to cast and/or coat filmsof the mixture on a medical device 10 to create a drug deliverystructure. After the films dry, they may be divided into two or moresets, one set may be stored under “ambient temperatures” and the secondset may be stored at a temperature (“refrigerated”) of between 2° C. -8°C. In this exemplary study, an initial analysis of each film's API wasmade the same day that the films were created and each film contained0.84 mg of mitomycin 16 per grams of polymer (PVP 14). Analysis of themitomycin 16 was done for both ambient and refrigerated samples ateleven (11) days after the start, twenty-one (21) days after the start,and one-hundred and one (101) days after the start, and for the ambienttemperature samples one-hundred and eighty-five (185) days after thecreation of the films.

Continuing to refer to FIG. 2, the analysis of the films at ambienttemperatures and at the refrigerated temperature of between 2° C.-8° C.showed that the films were stable and there were no significant changesto the API concentration. As seen in FIG. 2, the sample at the “ambient”temperature one (1) day after the creation of the film had 0.046 mg/mland the “refrigerated” temperature sample had 0.045 mg/ml. One-hundredand one (101) days after the films were made, the “ambient” temperaturefilms showed approximately a 2-5% decomposition of the mitomycin 16. Thepercentage change in the mitomycin 16 content was within the limits ofexperimental error, indicating that very little to no change in themitomycin 16 content of the films occurred. One-hundred and eighty-five(185) days after the films were created showed that the films stored atthe ambient temperature had not changed since the films were last lookedat 101 days after the films were created. Ultimately, the mixture of thePVP 14 and the mitomycin 16 was shown to be stable for at least 185 daysin ambient temperatures.

For example, The PVP 14 and mitomycin 16 mixture may be used withsolutions including methanolic and ethanolic solutions. Although PVP 14may be added to the mitomycin 16 as a mixture, other compounds may beadded to the PVP 14 and mitomycin 16 mixture or may be added to themitomycin 16 alone including, but not limited to, alginate, karaya gum,hydroxyethyl cellulose, hydroxypropyl cellulose, cellulose either,gelatin, polyvinyl alcohol, a biodegradable matrix, and/or another waterbased polymer. All of these materials may be used in combination withthe mitomycin 16 to create a bio-adhesive film.

As shown in FIGS. 3A and 3B, the medical device 10 may be a lacrimalpunctual plug 22. The lacrimal punctal plug 22 may be made out ofmaterial including polytetrafluoroethylene (“PTFE”), silicone rubber(polydimethyl siloxane), hydroxyethylmethacrylate (“HEMA”), and/orpolymethylmethacrylate (“PMMA”). Also, the lacrimal punctal plug 22 maybe coated with PVP 14 alone to make the surface of the punctal plug 22slick, to prevent debris from collecting on the surface, and to enhancedrainage. Some lacrimal punctal plugs 22 available on the market arecoated with PVP 14 alone. Generally, lacrimal punctal plug 22 diametersmay range from 0.3 millimeters (“mm”) to 1.3 mm and have a length ofbetween 1.0 mm and 2.0 mm, depending upon the size and dimensionsrequired by the particular patient. The diameter and the length of thepunctal plug 22 may be larger or smaller than the dimensions provideddepending upon the particular patient. One or more than one punctal plug22 may be used in the eye, such as in the corner of the eye.

Continuing to refer to FIGS. 3A and 3B, at least a portion of thepunctal plug 22 may be coated with the mixture of PVP 14 and mitomycin16. The punctal plug 22 may be treated with surface treatment methods,which may be used to improve adhesion of the PVP 14 and mitomycin 16coating to the punctal plug 22 surface, may include using corona plasmadischarge where a voltage between 10 to 20 kV may be applied through anair gap to ionize the atmospheric air which can create a polar groupthereby increasing surface tension and functionalizing the surface, achemical plasma discharge where plasma is generated using a low, a high,or a microwave frequency electric field by controlling the chemistry andpressure of the surrounding atmosphere, or with a flame plasma treatmentwhere natural gas is burned and creates a flame that oxidizes thesurface which results in the formation of hydroxyl, carboxyl, andcarbonyl functionalities. These surface treatment coating methods, aswell as others, may be used with different weights and line speeds andthe coating adhesion strength to the punctal plug 22 may depend on howlong after the particular treatment the coating of PVP 14 and mitomycin16 mixture is applied. Alternatively, these surface treatment coatingmethods may not be used and the PVP 14 and mitomycin 16 mixture may becoated directly onto an untreated surface.

Continuing to refer to FIGS. 3A and 3B, in an exemplary embodiment, thelacrimal punctal plug 22 may include the body 12 where the body 12includes an elongate portion of the body 24. This elongate portion ofthe body 24 may be any size or shape depending upon where and how themedical device is being used in the care and treatment of a patient andthe elongate portion of the body 24 may be sized to be received within apatient's lacrimal punctum. The elongate portion 24 may include a firstportion 26 and a second portion 28. The first portion of the elongateportion of the body 24 may have a first end 30 and this first end may berounded or blunted such that when the punctal plug 22 is inserted intothe tear duct opening of an eye, the rounded first end 30 may fitsecurely inside the punctum to prevent the loss of the punctal plug 22in the eye. The first end 30 may have a diameter that is greater than,equal to, and/or less than the diameter of the body 12. Alternatively,the first end 30 may be a variety of other shapes including having apoint like a cone, a square based pyramid, or a tetrahedron shape suchthat it may pierce through tissue. Also, as a non-limiting example, thefirst end 30 may not have any of PVP 14 and/or mitomycin 16 so that thefirst end 30 may come in direct contact with eye ball and/or the tearsof the eye and may minimize the amount of PVP 14 and/or mitomycin 16that comes into contact with the tears and the eye.

Continuing to refer to FIGS. 3A and 3B, the second portion 28 of theelongate portion of the body 24 may have a second end 32 and the secondend 32 may be expandable from a first diameter 34 as shown in FIG. 3A toa second diameter 36 as shown in FIG. 3B. The first diameter 34 may belarger or smaller than the second diameter 36. The first diameter 34 andthe second diameter 36 may be greater than, less than, and/or equal tothe diameter of the body 12 of the medical device 10. For example, asshown in FIG. 3A, the first diameter 34 may be smaller than the seconddiameter 36 such that when the medical device 10 is inserted into thetissue there is less obstruction and the medical device 10 is morestreamlined to aid in insertion of the device. Once the medical device10, such as the punctal plug 22, is inserted into the patient's tissue,as shown in FIG. 3B, the first diameter 34 may be expanded from thefirst diameter 34 to the second diameter 36 to help secure the medicaldevice 10 in place or to put at least a portion of the medical device 10into contact with particular tissue. In alternative embodiments, thefirst diameter 34 may be larger than the second diameter 36 such thatwhen the medical device 10 is inserted into tissue it may create alarger orifice which can make it easier for the remainder of the medicaldevice 10 to be inserted into the tissue. The sizing of the diameter maybe dependent upon where and how the medical device 10 is to be insertedinto tissue. Additionally, the first end 30 and/or the second end 32 maybe collapsible and/or expandable and retractable to assist in theinsertion and retention of the medical device 10 within the patient'stissue.

Continuing to refer to FIGS. 3A and 3B, the mixture of PVP 14 andmitomycin 16 may be coated onto at least a portion of the punctal plug22. For example, at least a portion of the punctal plug 22 may be dippedinto the mixture of PVP 14 and mitomycin 16, and then the mixture may beleft to dry to form a flexible, clear, and almost colorless film on thepunctual punctal plug 22. The punctal plug 22 may be dipped into themixture of PVP 14 and mitomycin 16 one time or more than one time. Forexample, the elongate portion of the body 24 of the punctual plug 22 maybe dipped into the mixture of PVP 14 and mitomycin 16 one time and thenthe mixture may be given time to dry. Once the mixture has dried on theelongate portion of the body 24 of the punctal plug 22, the elongateportion of the body 24 of the punctal plug 22 may be dipped a secondtime into the mixture of PVP 14 and mitomycin 16 and then this coatedmixture may be left to dry on the punctal plug 22. The number of timesthe punctal plug 22 is dipped into the mixture will depend upon how muchmixture is to be coated onto the medical device 10 as well as thethickness of this coating. This amount may depend upon where and how thepunctal plug 22 is going to be delivered to living tissue.

Continuing to refer to FIGS. 3A and 3B, alternatively, the PVP 14 andmitomycin 16 mixture may be painted onto the surface of the punctualplug 22 using, for example, a brush. As a non-limiting example, themixture of the PVP 14 and mitomycin 16 may be painted onto the elongateportion of the body 24 such that the mixture of the PVP 14 and mitomycin16 are not on the first end 30. Additionally, the PVP 14 and mitomycin16 mixture may be sprayed to coat the entire medical device 10 or aportion of the medical device 10. If a medical provider were to insertthe lacrimal punctal plug 22 into a portion of the eye by coming intocontact with the first end 30, the medical provider would not come intocontact with the mixture of the PVP 14 and the mitomycin 16, therebyminimizing the exposure to mitomycin 16. The use of the mixture ofmitomycin 16 and PVP 14 in the eye can reduce scar tissue by modifyingwound healing by using a medical device 10 that has a very targetedapplication to specific areas of tissue.

Continuing to refer to FIGS. 3A and 3B, the mixture of PVP 14 andmitomycin 16 may be applied in the form of a film or a patch. As anon-limiting example, the film may be produced by taking the mixture ofPVP 14 and mitomycin 16 and spreading it out onto a non-stick surface.For example, the non-stick film surface may include a coating with afluoropolymer or any other non-stick surface. The film may dry on thenon-stick surface and then be peeled off of the non-stick surface intothe film or patch. The film or patch may be made into any size or shape,including by using scissors to cut and shape the film/patch. The film orpatch may be placed on a surgical site of the body for the suppressionof scarring reactions. When the film or patch is placed over thesurgical site and exposed to water, for example within tissue, thefilm/patch may dissolve and deliver mitomycin 16 to the adjacent tissue.

Now referring to FIG. 4, the body 12 may define a cavity 38 and themixture of the PVP 14 and mitomycin 16 may be disposed within the cavity38. The cavity 38 may have at least one opening 39. The amount andquantity of the mixture of the PVP 14 and mitomycin 16 contained withinthe cavity 38 may depend upon the size of the cavity 38. The cavity 38may be filled with the mixture of PVP 14 and mitomycin 16 or only aportion of the cavity 38 may have the mixture of PVP 14 and mitomycin16. The mixture of the PVP 14 and mitomycin 16 may also be disposed onany portion of the body 12 of the medical device 10. The medical device10 may further include a bioabsorbable membrane 40 that may beconfigured to enclose at least a portion of the opening 39 of the cavity38. Alternatively, the bioabsorbable membrane 40 may enclose the entireopening 39 of the cavity 38 or may be found in any portion of the cavity38. The bioabsorbable membrane 40 may also coated on any portion of themedical device 10. For example, the bioabsorbable membrane 40 may beused to line a portion of the cavity 38 or all of the cavity 38. Whenthe bioabsorbable membrane 40 is in place and enclosing the opening 39of the cavity 38, it may secure the mixture of PVP 14 and mitomycin 16within the cavity 38 before the medical device 10 is placed into livingtissue. The bioabsorbable membrane 40 may be lubricious and may beconfigured to fully or partially enclose the opening 39 before themedical device 10 is inserted into body tissue. Once the medical device10 is inserted into body tissue, the bioabsorbable membrane 40 maydissolve so that the mixture of PVP 14 and mitomycin 16 may be releasedinto the tissue surrounding the medical device 10. The bioabsorbablemembrane 40 may also provide protection to a medical provider that isinvolved in the handling of the medical device 10 with the mixture ofPVP 14 and mitomycin 16 as well as with the insertion of the medicaldevice 10 into living tissue.

Now referring to FIG. 5, the medical device 10 may include a body 12with a surface 42 and the surface 42 may include at least one aperture44 and or the surface may be porous and/or permeable to water. In oneconfiguration, the mixture of PVP 14 and mitomycin 16 may be within thecavity 38 of the body 12 and the at least one aperture 44 and/or theporous/permeable surface may be permeable to water such that when themedical device 10 is inserted into tissue, the mixture of PVP 14 andmitomycin 16 may be dispersed from inside the cavity 38 to thesurrounding tissue that the medical device 10 is in contact with orclose to. This configuration of the medical device 10 may allow themixture of PVP 14 and mitomycin 16 to be placed within the cavity 38 sothat a medical provider does not come into contact with the mixture andthen once the medical device 10 is inside the tissue, the water withinthe tissue can cause the mixture to disperse within the tissue.

In FIG. 6, the medical device 10 may be a stent 46 which may be insertedinto the lumen of an anatomic vessel or duct. The stent 46 may be adrug-eluting stent or a non-drug eluting stent and the stent 46 may beused for a variety of different medical purposes and/or proceduresincluding cardiovascular, urological, reproductive, nephrological,neurological, ophthalmological, otolaryngologic, muscular, and forissues related to body piercings. The stent 46 may have an exterior thatis mesh 48, an annular coil, a tubular shape, a ganglion-shape as wellas any other shape that is appropriate for the purpose and body partthat the stent 46 is going to be used within. In an exemplaryembodiment, the stent 46 may be a mesh 48 stent and the mesh 48 may becoated with an exterior coating 20 which may be dissolvable once thestent 46 is inserted into tissue. The mixture of PVP 14 and mitomycin 16may be placed in the cavity 38 within the stent 46, and once theexterior coating 20 dissolves, the mixture of PVP 14 and mitomycin 16may be dispersed within the patient's tissue as the tissue may includewater and the PVP 14 and mitomycin 16 mixture may be dissolvable inwater. In another exemplary configuration, the PVP 14 and mitomycin 16may be coated onto the stent 46 and allowed to dry on the stent 46. Oncethe stent 46 is inserted into tissue, the water within the tissue maycause the coating of the PVP 14 and the mitomycin 16 to dissolve withinthe tissue.

Now referring to FIG. 7, the medical device 10 may have an elongate body12 with the first portion 26 being opposite the second portion 28. Theelongate body 12 may be cylindrical and taper in diameter from the firstportion 26 to the second portion 28. The first portion 26 may have adiameter D1 and the second portion 28 may have a diameter D2 that iseither smaller than, equal to, or larger than the diameter D1 of thefirst portion 26. The first portion 26 may have a first end 30 and thefirst end 30 may be expandable from a first diameter to a seconddiameter. Alternatively, the second portion 28 may have a second end 32and the second end 32 may be expandable from a first diameter to asecond diameter as well. In alternative embodiments, the first enddiameter and the second end diameter may be expandable to a variety ofdifferent diameters depending upon the tissue that the medical device 10is being inserted into. The mixture of PVP 14 and mitomycin 16 may becoated onto at least a portion of the elongate body 12. Alternatively,the mixture of PVP 14 and mitomycin 16 may be coated on the entireelongate body 12. This coating may be covered by a bioabsorbablemembrane 40 or it may simply be coated onto the elongate body 12. Whenthe elongate body 12 is inserted into a patient's tissue, thebioabsorbable membrane 40 and the PVP and mitomycin 16 mixture may bedissolvable in the tissue.

Now referring to FIG. 8 the medical device 10 may have an elongate body12 that may be cylindrical and taper in diameter from the first portion26 to the second portion 28. At least a portion of the first portion 26may have a diameter D3 and at least a portion of the second portion 28may have a diameter D4. The diameter D3 may be the widest diameter ofthe medical device and if the medical device 10 is inserted into aportion of the body, at least a portion of the first portion 26 may beon the exterior of the body while the second portion 28 may be in theinterior of the body. The elongate body 12 may further include one ormore lumens 50 thereby providing mechanical, electrical, and/or fluidcommunication between the first portion 26 and the second portion 28 ofthe medical device 10. For example, a lumen 50 may be used for theintroduction and passage of a guide wire and/or a treatment ordiagnostic instrument (not shown). The lumen 50 may also be used for thepassage or delivery of a fluid from the first portion 26 of the medicaldevice 10 to the second portion 28 of the medical device. The medicaldevice 10 may further include one or more apertures 52 or openingstherein, to provide for example, for the dispersion or directed ejectionof fluid from the lumen 50 to the environment exterior to the lumen 50.Mitomycin 16 and PVP 14 may be coated on all or part of the medicaldevice 10. As shown in FIG. 8, the mitomycin 16 and PVP 14 may be coatedon at least a portion of the elongate body 12. The first portion mayalso have a removal device 54 such as a string, a suture, or a threadwhich can be used to remove the medical device 10 after it has beeninserted into a portion of a patient's body. For example, after themedical device 10 is inserted into tissue, the removal device 54 may bepulled on to extract the medical device 10 from the patient's tissue.The medical device 10 may be made out of silicon, metal, glass,polytetrafluorethylene, polymer, plastic, and/or niobium. The medicaldevice 10 may be used in, for example, a patient's eustachian tubes,urethra, nose, esophagus, trachea, and/or another orifice in the body.

Now referring to FIG. 9, the medical device 10 may be inserted intoliving tissue. The insertion of the medical device 10 into living tissuemay be done with any of the embodiments discussed in FIGS. 1-8 as wellas any other medical device 10 that contains a mixture of PVP 14 andmitomycin 16. As shown in S100, the body 12 may be inserted into aliving tissue and the body may include a mixture of PVP 14 and mitomycin16. This insertion may take place with a medical device 10 that has ablunted portion or a sharp portion that is configured to puncture tissuesuch as a pointed end. Alternatively, a needle or another device may beused to puncture the tissue and then the medical device 10 may beinserted into the tissue area that has been punctured. The body 12 maybe advanced into the living tissue and this may be done quickly orslowly S102. The mixture of the PVP 14 and the mitomycin 16 willdisperse into the living tissue as this mixture is water-soluble S104.The mixture of the PVP 14 and the mitomycin 16 may completely disperseinto the living tissue or it may only partially disperse into the livingtissue. The amount of the mixture that is dispersed may depend upon howlong the medical device 10 remains within the living tissue, thematerial that is used with the medical device 10 and how it allows themixture to disperse into the living tissue, as well as how much water isin the tissue. Additionally, the type of tissue that the medical device10 is inserted into may impact how the mixture of mitomycin 16 and PVP14 is dispersed. After the desired amount of PVP 14 and mitomycin 16 hasdispersed into the tissue, the body 12 of the medical device 10 may beremoved from the living tissue. S106 Alternatively, the body 12 of themedical device 10 may remain in the living tissue and/or the body 12 maydissolve in the living tissue and therefore not require the removal ofthe body from the living tissue.

It will be appreciated by persons skilled in the art that the presentinvention is not limited to what has been particularly shown anddescribed herein above. In addition, unless mention was made above tothe contrary, it should be noted that all of the accompanying drawingsare not to scale. A variety of modifications and variations are possiblein light of the above teachings without departing from the scope andspirit of the invention, which is limited only by the following claims.

What is claimed is:
 1. A medical device, comprising: a body including; amixture of polyvinylpyrrolidone (“PVP”) and mitomycin coated on at leasta portion of the body; and an elongate portion having a first portionand a second portion opposite the first portion, the first portionhaving a rounded first end that is not coated with the mixture of PVPand mitomycin.
 2. The medical device of claim 1, further comprising anexterior coating where the mixture of PVP and mitomycin is coated withthe exterior coating.
 3. The medical device of claim 2, wherein theexterior coating is lubricious.
 4. The medical device of claim 1,wherein the second portion has a second end, the second end beingexpandable from a first diameter to a second diameter.
 5. The medicaldevice of claim 1, wherein the body defines a cavity, the mixture of thePVP and the mitomycin being disposed within the cavity.
 6. The medicaldevice of claim 5, further including a bioabsorbable membrane enclosingat least a portion of the cavity.
 7. The medical device of claim 6,wherein the body has a surface, the surface including at least oneaperture.
 8. The medical device of claim 1, wherein the body is a stent.9. The medical device of claim 1, wherein the mixture of PVP andmitomycin further includes at least one selected from the groupconsisting of alginate, karaya gum, cellulose ether, gelatin, andpolyvinyl alcohol.
 10. A medical device, comprising: a body including:an elongate portion having: a first portion having a rounded first end;a second portion opposite the first portion; and a longitudinal axisdefined therebetween, the second portion being transitionable between afirst retracted configuration and a second extended configuration alongthe longitudinal axis, the second portion extending farther away fromthe first portion when in the second extended configuration than when inthe first retracted configuration; and a mixture of polyvinylpyrrolidone(PVP) and mitomycin.
 11. A medical device, comprising: a body includinga mixture of polyvinylpyrrolidone (“PVP”) and mitomycin, the mixtureincluding: approximately 1.0 mg/g of a mitomycin solution having:approximately 30.0 mg of mitomycin; and approximately 29.970 mg ofabsolute ethanol; approximately 1.360 g of PVP; and approximately 0.090g of a PVP copolymer.
 12. The medical device of claim 11, wherein themixture of PVP and mitomycin further includes at least one selected fromthe group consisting of alginate, karaya gum, cellulose ether, gelatin,and polyvinyl alcohol.
 13. The medical device of claim 9, wherein thecellulose ether is one selected from hydroxyethyl cellulose andhydroxypropyl cellulose.
 14. The medical device of claim 12, wherein thecellulose ether is one selected from hydroxyethyl cellulose andhydroxypropyl cellulose.